Log in

Relevant bibliographies by topics / Antibiotics and bronchiectasis

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers
Reports

Academic literature on the topic 'Antibiotics and bronchiectasis'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antibiotics and bronchiectasis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antibiotics and bronchiectasis"

1

Suarez-Cuartin, Guillermo, Marta Hernandez-Argudo, Lidia Perea, and Oriol Sibila. "Long-Term Antibiotics in Bronchiectasis." Seminars in Respiratory and Critical Care Medicine 42, no. 04 (July 14, 2021): 606–15. http://dx.doi.org/10.1055/s-0041-1730945.

Full text

Abstract:

AbstractA significant proportion of bronchiectasis patients are chronically infected by potentially pathogenic microorganisms which may lead to frequent exacerbations and worse clinical outcomes. Current bronchiectasis guidelines recommend long-term inhaled antibiotics and/or oral macrolides as a part of patient management. In recent years, an increasing amount of evidence assessing the impact of these treatments on patient outcomes has been collected. Inhaled antibiotics have demonstrated significant improvements in sputum bacterial load, but their impact on patient quality of life, lung function, and exacerbation rate has not been consistent across trials. In this regard, recent post hoc analyses of inhaled antibiotics trials in bronchiectasis patients have shown that sputum bacterial load may be a key biomarker to predict treatment response in these patients. Oral macrolides, on the other hand, have proven to reduce exacerbation frequency and improve quality of life, but potential drug-related adverse effects and the increase in bacterial resistance are relevant. This review aims to summarize current important evidence for long-term antibiotic treatment in bronchiectasis patients.

APA, Harvard, Vancouver, ISO, and other styles

2

Polverino, Eva, Edmundo Rosales-Mayor, and VictoriaAlcaraz Serrano. "Inhaled antibiotics in bronchiectasis." Community Acquired Infection 2, no. 1 (2015): 8. http://dx.doi.org/10.4103/2225-6482.153856.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

T. King, Paul, and Peter W. Holmes. "Use of Antibiotics in Bronchiectasis." Reviews on Recent Clinical Trials 7, no. 1 (February 1, 2012): 24–30. http://dx.doi.org/10.2174/157488712799363280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nadig, Tejaswi R., and Patrick A. Flume. "Aerosolized Antibiotics for Patients with Bronchiectasis." American Journal of Respiratory and Critical Care Medicine 193, no. 7 (April 2016): 808–10. http://dx.doi.org/10.1164/rccm.201507-1449le.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

OBILIŞTEANU, Gabriela C., Alexandru MATEI, Loredana MANOLESCU, Viviana DRAGODAN, Ruxandra ULMEANU, and Florin D. MIHĂLŢAN. "Updated therapies in bronchiectasis." Romanian Journal of Medical Practice 12, no. 2 (June 30, 2017): 91–96. http://dx.doi.org/10.37897/rjmp.2017.2.6.

Full text

Abstract:

Objective. The aim of this study is to evaluate the constantly updated and integrated treatment strategies for the improvement and the cure of bronchiectasis, with a beneficial effect on the quality of life of patients diagnosed with this disease. Material and method. The retrospective study (december 17th 2014 – june 2nd 2015), was conducted on 89 patients hospitalised in the Pneumophtysiology Institute "Marius Nasta" in Bucharest, with the confirmed clinical diagnosis of non cystic fibrosis bronchiectasis. From the clinical observation charts of the patients included in the study, we evaluated the treatment strategies applied for each patient in correlation with the confirmed clinical diagnosis. The therapies applied included antimicrobial, mucolytic, bronchodilator, corticosteroid, immunotherapy treatment, pulmonary rehabilitation, treatment of associated disease (ORL and gastro-oesophageal reflux), hygiene diet and antidepressant treatment. Results. The microbial etiology identified in the sputum (17,97%) consisted of Haemophilus influenzae, Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus parainfluenzae, Streptococcus pyogenes and Candida albicans, 82,03% of the cases presented non-specific (normal) flora. The associated therapy of antibiotic treatment (cephalosporin + fluoroquinolone) + mucolytic agent (erdosteine) + corticosteroid & β adrenergic agonist + anticolinergic agent + nonsteroid anti-inflammatory + anti-influenza vaccination + immunotherapy was the most efficient and the most used first-intention therapeutic association (35/39,32%). All the patients were discharged with improved bronchiectatic status. Discussions. The present study, with multiple date regarding the treatment of the acute disease, revealed the importance and the benefit of the multitype therapy, continuously updated, for the treatment of bronchiectasis of various degrees of severity. In time, the treatment can have serious side effects for the patient and the community in regard to antibiotic resistance; the severity and the complications' risk offers an useful background for taking clinical decisions that patients require long term treatment courses, such as macrolides, airway adjuvants, inhalatory antibiotics and other measures. Conclusions. Future studies should refer to a greater number of patients with varying degrees of severity of this disease, with more specific etiological information and with a longer duration, to clarify the actual benefits of new promising therapies and to offer new perspectives on the medical approach of bronchiectasis.

APA, Harvard, Vancouver, ISO, and other styles

6

Gross-Hodge, Ellen, Will D. Carroll, Naomi Rainford, Carrol Gamble, and Francis J. Gilchrist. "Duration of initial antibiotic course is associated with recurrent relapse in protracted bacterial bronchitis." Archives of Disease in Childhood 105, no. 11 (October 17, 2019): 1111–13. http://dx.doi.org/10.1136/archdischild-2019-317917.

Full text

Abstract:

Protracted bacterial bronchitis (PBB) is the leading cause of chronic wet cough in young children from developed countries. Despite its high prevalence there is a paucity of evidence to inform the optimal duration of treatment leading to variation in practice. Relapse of chronic cough is common and recurrent PBB (>3 episodes in 12 months) is associated with a future diagnosis of bronchiectasis. We investigated the factors associated with any relapse (≥1 episode in 12 months) and recurrent PBB in 66 children. No factor was significantly associated with any relapse. Duration of initial antibiotic treatment was the only factor significantly associated with recurrent PBB. Those who received antibiotics for 6 weeks antibiotics were less likely to develop recurrent PBB than those who received for 2 weeks (p=0.046). This is the first study to show an association between duration of initial antibiotic course and therefore future bronchiectasis. Prospective studies are needed to investigate this association.

APA, Harvard, Vancouver, ISO, and other styles

7

Webb, Philip, Jenny King, Caroline Baxter, and Robert W. Lord. "Management of non-cystic fibrosis bronchiectasis." British Journal of Hospital Medicine 82, no. 7 (July 2, 2021): 1–9. http://dx.doi.org/10.12968/hmed.2020.0739.

Full text

Abstract:

Bronchiectasis is a common respiratory condition, characterised by abnormal bronchial dilatation, that often leads to recurrent airway infection and inflammation. It is an increasingly recognised respiratory condition, both as a primary lung disease but also co-existing with other respiratory diseases, such as chronic obstructive pulmonary disease and asthma. Diagnosis can have important treatment implications. There are shared systematic approaches to treatment, such as sputum clearance techniques, prompt treatment of exacerbations and, in certain circumstances, regular antibiotic therapy. It is vital to target antibiotic therapy appropriately, and knowledge of the patient's airway microbiology can assist with this. Certain infective and colonising organisms, such as Pseudomonas aeruginosa, cause worse patient outcomes and so need prompt treatment with appropriate antibiotics. In addition to this general management approach, there are many different underlying causes of bronchiectasis that should be identified wherever possible, to support more targeted therapy and prevent disease progression. This article provides a guide to the key principles of diagnosing and managing bronchiectasis, and outlines situations where more specialist respiratory support is required.

APA, Harvard, Vancouver, ISO, and other styles

8

Choi, Hayoung, Hyun Lee, Seung Won Ra, and Yeon-Mok Oh. "Update on pharmacotherapy for adult bronchiectasis." Journal of the Korean Medical Association 63, no. 8 (August 10, 2020): 486–92. http://dx.doi.org/10.5124/jkma.2020.63.8.486.

Full text

Abstract:

Bronchiectasis refers to abnormal dilatation of the bronchi, which leads to the failure of mucus clearance and increased risk of infection. Pharmacotherapy for stable bronchiectasis includes oral or inhaled mucoactive agents, anti-inflammatory therapy, inhaled bronchodilators, long-term antibiotics, and long-term macrolide treatment. Among them, mucoactive agents are the most common adjunctive agents to airway clearance techniques. When patients with impaired lung function suffer from dyspnea, inhaled bronchodilators may be prescribed to relieve the symptom. Long-term macrolide treatment has been proven to prevent exacerbation in patients with frequent bronchiectasis exacerbation. If exacerbation occurs despite the above mentioned treatments, one or two weeks of antibiotics should be prescribed to cover respiratory bacteria that include <i>Pseudomonas aeruginosa</i>. Because evidence supporting the use of pharmacotherapy for bronchiectasis is weak, further research is warranted.

APA, Harvard, Vancouver, ISO, and other styles

9

Rubin, Bruce K. "Aerosolized Antibiotics for Non-Cystic Fibrosis Bronchiectasis." Journal of Aerosol Medicine and Pulmonary Drug Delivery 21, no. 1 (March 2008): 71–76. http://dx.doi.org/10.1089/jamp.2007.0652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Rubin, Bruce K., and Ronald W. Williams. "Aerosolized Antibiotics for Non-Cystic Fibrosis Bronchiectasis." Respiration 88, no. 3 (2014): 177–84. http://dx.doi.org/10.1159/000366000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antibiotics and bronchiectasis"

1

Hill, S. L. "The effect of antimicrobial therapy on lung secretions in bronchiectasis." Thesis, Coventry University, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.383413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

McSorley, James Charles. "Pre-clinical studies on novel lipid therapeutics with anti-virulence and antibiotic synergising potential against Pseudomonas aeruginosa isolates from bronchiectatic airways." Thesis, University of Strathclyde, 2016. http://digitool.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=29509.

Full text

Abstract:

Chronic infections of the airways remain the leading cause of mortality in cystic fibrosis. Antibiotic therapy has drastically improved survival in this patient cohort, however, this therapy seldom, if ever, results in bacteriologic eradication of the infecting organism and acts only to suppress infection. The efficacy of such therapy may also be undermimed by the emergence of drug resistant strains, some of which may also display enhanced virulence and this is further confounded by the fact that antibiotic development has virtually drawn to a halt in recent decades. It is therefore imperative that potential alternatives to conventional antibiotics are sought to aid management of these infections. Use of phospholipid vesicles in these conditions may be one such alternative. Here, the potential of a multi-lamellar liposome based upon host lamellar bodies, LMS-611, to act as an anti-virulence agent and antibiotic synergist is explored in vitro with clinical isolates of the respiratory pathogen Pseudomonas aeruginosa. LMS-611 was found to reduce accumulation of elastase, pyocyanin, exopolysaccharide and the siderophores pyoverdine and pyochelin. LMS-611 does not reduce biofilm accumulation or viability in these models but microscopic evidence suggests that it modifies biofilm architecture, leading to the formation of homogenous layers rather than differentiated three dimensional structures. Studies are also conducted upon micelles composed of monopalmitoylphosphatidic acid (MPPA), a lysophospholipid which occurs naturally in inflammatory exudates and has previously been reported to have anti-microbial effects. It is discovered that MPPA reduces accumulation of pyocyanin by some strains and it is suggested on the basis of gene expression, growth kinetics and phenotype microarrays that this may be the result of enhanced growth and catabolite repression. Hitherto unknown interactions of MPPA with non β-lactam antibiotics are also uncovered and possible reasons suggested for these. Paradoxically, it is found that MPPA increases both biofilm accumulation and swimming motility.

APA, Harvard, Vancouver, ISO, and other styles

3

Twiss, Jacob. "Childhood bronchiectasis: national incidence, disease progression and an evaluation of inhaled antibiotic therapy." 2008. http://hdl.handle.net/2292/5747.

Full text

Abstract:

Background: Bronchiectasis is a chronic suppurative lung disease, defined by dilatation of bronchial airways, resulting in significant morbidity, mortality, and healthcare expenditure. It continues to affect large numbers of people worldwide, particularly indigenous or disadvantaged communities. The goals of this thesis were to determine childhood bronchiectasis occurrence in New Zealand, define its progression, and evaluate a potential new therapy; inhaled antibiotics. Methods: Firstly, a single-centre retrospective study described the prevalence, aetiology and severity of childhood bronchiectasis in Auckland. Secondly, a two year prospective multi-centre study described the incidence, aetiology and severity of new cases of bronchiectasis in New Zealand. Thirdly, disease progression was estimated through retrospective linear mixed-model analyses of pulmonary function and compared to peers with cystic fibrosis. Fourthly, an evaluation of inhaled gentamicin pharmacokinetics was made through a single-dose open-label study. Finally, a randomised double-blinded placebo-controlled two-period community-based crossover trial of inhaled antibiotics was conducted. Results: Children identified had severe, extensive bronchiectasis with an Auckland prevalence of 1:3000 and a national incidence of 3.7:100,000 per year. Compared with New Zealand children of European ethnicity, the incidence was 12 times higher in Pasifika and 3 times higher in Maori. Pneumonia, poverty, immunodeficiency, aspiration and recent immunosuppressive therapy were the most important aetiologies. Children with bronchiectasis had more severe obstructive lung disease than peers with cystic fibrosis (FEV1 intercept at ten years age 63% versus 77% predicted, p<0.001) but declined more slowly (-0.9% versus -2.5% predicted per annum, p=0.02). Inhaled gentamicin (80mg) safely achieved target concentrations within sputum (mean 697 μg/g). Despite low adherence, inhaled gentamicin was well tolerated, resulted in reduced symptoms, decreased Haemophilus influenzae density (-2.7 log10 cfu/ml, p<0.001), decreased airway inflammation (neutrophils, IL-1β, IL-8, TNFα) and reduced oral antibiotic use (OR 0.19, p<0.001). No significant change in spirometry or hospitalisation rates occurred over the three months. Conclusion: Childhood bronchiectasis has a high and increasing prevalence in New Zealand, especially in Pasifika and Maori. Children have extensive, progressive disease despite ‘standard’ management. Inhaled gentamicin is well tolerated, achieves effective concentrations, improves symptoms, reduces bacterial load and airway inflammation aswell as oral antibiotic use. However, low adherence suggests poor acceptability.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antibiotics and bronchiectasis"

1

Shteinberg, Michal, Chris Johnson, and Charles Haworth. "Long-Term Inhaled Antibiotic Treatment in Bronchiectasis." In Bronchiectasis, 223–39. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-61452-6_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Goeminne, Pieter Christian, and Menno Van der Eerden. "Long-Term Oral Antibiotic and Anti-inflammatory Treatment." In Bronchiectasis, 241–56. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-61452-6_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Everett, M. T. "Bronchitis, Bronchiolitis and Bronchiectasis." In Selective Antibiotic Use in Respiratory Illness: a Family Practice Guide, 159–68. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-015-1143-8_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Milliron, Bethany, Brent P. Little, and Travis S. Henry. "Bronchiectasis." In Chest Imaging, 319–23. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780199858064.003.0055.

Full text

Abstract:

Bronchiectasis represents irreversible bronchial dilatation. It can be focal or diffuse, and usually results from chronic infection, proximal airway obstruction, or a congenital bronchial abnormality. Traction bronchiectasis refers to irregular bronchial dilatation in the setting of surrounding pulmonary fibrosis. Patients with cystic fibrosis have a progressively worsening clinical course, with recurrent pneumonias and chronic airway colonization. Even with lung transplantation and modern antibiotic therapies, average life expectancy of cystic fibrosis patients remains limited to young adulthood. Non-cystic fibrosis related bronchiectasis can cause chronic cough and recurrent lung infection. Pulmonary function testing often reveals evidence of obstruction. Treatment of patients with mild to moderate bronchiectasis involves supportive care with bronchodilators, antibiotics, and other medical therapy. Surgical resection is uncommon, and usually reserved for cases of significant bronchiectasis limited to a single region of the lungs (such as a particular lobe or segment).

APA, Harvard, Vancouver, ISO, and other styles

5

Ali Kamal, Yasser. "Surgical Management of Bronchiectasis." In Update in Respiratory Diseases. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.93103.

Full text

Abstract:

Bronchiectasis is a chronic clinicopathological disease of the lung characterized by chronic cough, sputum production, recurrent pulmonary infection, and persistent bronchial dilatation on computed tomography. For many years, bronchiectasis associated with high mortality and morbidity particularly before the advent of antibiotics. The medical treatment of bronchiectasis includes antibiotic therapy, airway clearance, bronchodilators, and anti-inflammatory agents. Surgery is mainly performed for localized disease after failure of the medical treatment, including: segmentectomy, lobectomy, and pneumonectomy. This chapter highlights the current surgical considerations for treatment of bronchiectasis, regarding indications of surgery, preoperative evaluation and preparation, available operative procedures, postoperative outcomes, and other important surgical issues.

APA, Harvard, Vancouver, ISO, and other styles

6

Haworth, C. S. "Antibiotic treatment strategies in adults with bronchiectasis." In Bronchiectasis, 211–22. European Respiratory Society, 2011. http://dx.doi.org/10.1183/1025448x.10004410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Robinson, Terry, and Jane Scullion. "Bronchiectasis." In Oxford Handbook of Respiratory Nursing, 215–34. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198831815.003.0008.

Full text

Abstract:

Bronchiectasis is defined as irreversible bronchial wall dilatation and thickening. It may present clinically with recurrent chest infections, cough, chronic sputum production, shortness of breath, pleuritic chest pain, fatigue, and malaise. It can occur as a result of a primary infection, toxic insult occurring at any time from childhood to late adulthood, immunodeficiencies, some inflammatory conditions, and some inherited conditions such as primary ciliary dyskinesia and cystic fibrosis, but in approximately 50% of cases no underlying cause is found. This chapter covers the causes, clinical features, and management of bronchiectasis, including antibiotic treatment. Other infections that may occur are also explained, and monitoring regimes are indicated.

APA, Harvard, Vancouver, ISO, and other styles

8

Naji, Nizar, and Paul M. O’Byrne. "Bronchiectasis." In Asthma, 92–102. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199918065.003.0008.

Full text

Abstract:

Bronchiectasis is one of the most debilitating chronic respiratory diseases, which affects all ages, with significant morbidity and mortality. It is recognized clinically by chronic persistent daily cough, productive of mucopurulent sputum. The defining characteristic is the permanent abnormal dilatation and destruction of bronchial walls, which involve both the major bronchi and bronchioles. It is a major contributor to progressive lung function decline and functional disability, especially in patients with respiratory comorbidities. Bronchial hygiene, to clear airway secretions, is the basis of management. Bronchodilators and fixed-dose combination therapy with an inhaled corticosteroid and a long-acting β‎-agonist provide clinical benefit, but do not reduce the risks for acute exacerbations. The airways of patients with bronchiectasis are often colonized with pathologic bacteria, and acute exacerbations require antibiotic therapy. Allergic bronchopulmonary aspergillosis often requires daily oral corticosteroids for management.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antibiotics and bronchiectasis"

1

Njafuh, Raymond, Jill Patten, Tom Jones, Anna Newman, and Ben Green. "Bronchospasm secondary to nebulised antibiotics in bronchiectasis." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Goyal, Vikas, Keith Grimwood, Rob Ware, Catherine Brynes, Peter Morris, Ian Masters, Gabrielle Mccallum, et al. "Oral antibiotics vs placebo for exacerbations of paediatric bronchiectasis." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.rct5101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Anning, Louise, Mhairi McNeill, Alexander Rose, Hilary Mortimer, and Nicholas Withers. "The use of home intravenous antibiotics in adult non-CF bronchiectasis." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Donaghy, Michaela, Charlotte Addy, Jenny Mclornan, Oonagh Hewitt, Ruth Redfern, Damian Downey, and Steven Caskey. "The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.2369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Davison, J., D. McEvoy, G. Davies, R. Lee, T. Rapley, and A. De Soyza. "P58 A qualitative and quantitative assessment of patients’ attitudes to pulmonary targeted antibiotics in bronchiectasis." In British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2017. http://dx.doi.org/10.1136/thoraxjnl-2017-210983.200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Altenburg, Josje, James Chalmers, Mike Lonergan, Lata Jayaram, Lucy Burr, Megan Crichton, Noel Karalus, et al. "Long term macrolide antibiotics for the treatment of bronchiectasis in adults - individual participant data meta-analysis." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.oa4945.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Davison, John, Donna McEvoy, Gareth Davies, Richard Lee, Rapley Tim, and Anthony De Soyza. "Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients' attitudes." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

McKerr, Caroline, Adam Massey, Geraldine Lynch, and Nabil Jarad. "Factors associated with the need of intravenous antibiotics in a cohort of adult patients with non-CF bronchiectasis." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kaponi, Maria, Theodoros Karampitsakos, Argyris Tzouvelekis, Serafeim Chrysikos, Myrsini Melachroinidou, Anna Gousiou, Demosthenes Bouros, Christina Triantafillidou, and Katerina Dimakou. "Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa1971.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Laska, Irena F., Megan L. Crichton, Amelia Shoemark, and James D. Chalmers. "The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antibiotics and bronchiectasis"

1

Henkle, Emily, Benjamin Chan, Megan Wardrop, and Kevin Winthrop. Comparing Treatment with Long-Term Steroids or Long-Term Antibiotics to Prevent Lung Infections in Patients with Bronchiectasis. Patient-Centered Outcomes Research Institute (PCORI), September 2020. http://dx.doi.org/10.25302/09.2020.cer.150329191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Long-term macrolide antibiotics reduce risk of exacerbations of bronchiectasis. National Institute for Health Research, October 2019. http://dx.doi.org/10.3310/signal-000831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!